DIVYA RAJAGOPAL

  • Covid-19: Indian pharma companies want government to airlift APIs from China

    Covid-19: Indian pharma companies want government to airlift APIs from China

    IPCA Labs, Zydus Takeda, Mangalam Drugs & Organics and Wallace Pharma are among the manufacturers of this drug that are staring at fluctuating freight rates, a jump in prices of bulk drugs from Chinese suppliers and an erratic supply chain with cancelled or reduced frequency of cargo flights.

    ICMR approves antibody tests in hotspots

    ICMR approves antibody tests in hotspots

    ICMR said in an interim advisory that antibody tests can be carried out in hotspots – zones suspected to have widespread prevalence of the disease. Those testing positive for antibodies will be made to do RT-PCR tests, which can reveal the presence of virus, and will be quarantined at home.

    Covid-19: Private labs face home testing hiccups

    Covid-19: Private labs face home testing hiccups

    Several private labs say they are stuck between following state government directives and ICMR guidelines, such as home collection of samples. This is allowed by the ICMR, which also lists 16,000 collection centres across the country. However, some states have banned home collection & have even stopped labs from conducting tests at their own facilities.

    Two Mumbai companies step up work on COVID-19 drug helping in recovery

    Two Mumbai companies step up work on COVID-19 drug helping in recovery

    Mumbai-based BDR Pharma, which makes anti-HIV and Hepatitis C medication, and LASA Supergenerics, an active pharmaceutical ingredient maker, are betting that the drug works. While BDR has started lab work to get the initial samples out, it has several hurdles to cross before the product hits the market, the biggest being getting the actual reference product shipped from China.

  • No blogs yet have been written by the author, we’re sure the author will contribute one soon

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service